Resolvin E1 (RvE1) is a trihydroxy eicosapentaenoic acid metabolite that has been identified in mouse inflammatory exudates and in human plasma when subjects are treated with both aspirin and supplemental EPA. RvE1 is an anti-inflammatory EPA metabolite that has been shown to promote inflammatory resolution in numerous disease models, including experimental colitis, asthma, atherosclerosis, type 2 diabetes, and HSV-1-induced stromal keratitis.